Novos trial shows cardiovascular benefits in aging adults
Novos reported a company-run clinical trial in adults aged 40+ that found statistically significant reductions in systolic and diastolic blood pressure alongside improved lipid profiles and metabolic markers following its personalised lifestyle and metabolic-optimisation programme, and the company says it will share detailed data for external validation.
Why it mattersNovos' trial showed reduced systolic blood pressure and improved lipids, so clinics should pilot its programme.